The b-chemokine receptor CCR5, a G-protein-coupled seven-transmembrane domain receptor, has been shown to act as a major co-receptor for fusion and entry of macrophagetropic (M-tropic or R5) HIV-1 into the host cells.
Compound 1 has been selected as a clinical candidate for development as a subcutaneous injectable agent since it exhibited poor oral absorption owing to the quaternary ammonium moiety. However, in the course of the investigation of quaternary ammonium derivatives, it was found that the chemical precursor of 1, benzocycloheptene derivative 2 containing a tertiary amine moiety, exhibited CCR5 antagonistic activity with an IC 50 value of 0.95 mM in the binding assay. In addition, since 2 exhibited considerably better oral absorption than quaternary ammonium derivative 1, 2 was used as a starting point to develop orally active small molecule CCR5 antagonists. In order to improve the potency of tertiary amine derivatives, conversion of the benzocycloheptene ring of lead compound 2 to other condensed-heterocycle rings such as 1-benzothiepine and 1-benzazepine was investigated, and the synthesis of these derivatives is described.
Chemistry
The synthetic routes to the 1-benzothiepine, 1-benzothiepine-1-oxide and 1-benzothipine-1,1-dioxide derivatives are outlined in Chart 1. The benzothiepine ring was constructed by intramolecular Friedel-Crafts reaction of 4, which was prepared by the alkylation of p-bromothiophenol 3 with ethyl 4-bromobutyrate and subsequent alkaline hydrolysis. The resulting bromide 5 was condensed with 4-methylphenylboronic acid by Suzuki coupling reaction to give the ketone 6. Subsequent methoxycarbonylation gave the b-keto-ester, which was reduced using sodium borohydride, and dehydrated via mesylation to give the a,b-unsaturated esters 7. Benzothiepine-1,1-dioxide 8 was obtained by m-chloroper- benzoic acid (mCPBA)-oxidation of 7. Alkaline hydrolysis of the esters (7, 8) afforded carboxylic acids (9a, 9b), which were coupled with 4-[N-methyl-N-(tetrahydropyran-4-yl)-aminomethyl]aniline 10 7) to provide the desired products (11a, 11b). Oxidation of benzothiepine 11a using mCPBA gave benzothiepine-1-oxide derivative 11c.
Next, the synthesis of 1-methyl-1-benzazepine derivative 18 was carried out according to Chart 2. 4-{[(Benzyloxy)carbonyl]amino}butanoic acid 12 was N-methylated, tert-butylesterified, and deprotected by hydrogenation to give tertbutyl 4-(methylamino)butanoate 13. The condensation of ester 13 with 5-bromo-2-fluorobenzaldehyde 14 gave substituted 2-aminobenzaldehyde 15. The benzazepine ring 16a was constructed by Dieckmann-type condensation of aldehyde 15, using potassium tert-butoxide in good yeild (77%). Suzuki coupling reaction of 16a with 4-methylphenylboronic acid gave 16b which was converted to 17 by acid hydrolysis. Condensation of 17 with aniline 10 gave the desired anilide 18. Further details are to be found in Table 2 and the Experimental Section.
Results and Discussion
The synthesized compounds, benzocycloheptene 2, the benzoxepine 19, and a variety of tertiary amine derivatives 20-25 7) were evaluated for their inhibitory effects on chemokine binding to CCR5-expressing CHO cells. Binding assays were performed in the presence of [
125 I]-RANTES and the results are summarized in Tables 1 and 2 as IC 50 values. The effect of changing the tertiary amine group of lead compound 2 for benzocycloheptene and 1-benzoxepine derivatives is shown in Table 1 . Generally, the SAR of the tertiary amine moiety was similar to those of the corresponding quaternary ammonium moiety previously reported.
7) The piperidines (20, 21) were less active compared with the bulkier N-(a-branched alkyl)-N-methylamines (2, 19, 22-25). The 4-oxocyclohexyl 23 and 3-pentyl 24 derivatives were comparable to tetrahydropyran-4-yl 19, which was about twice as active as the benzocycloheptene 2. Since quaternary ammonium compound 1 exhibited similar potency to the corresponding 1-benzoxepine compound 26 (IC 50 ϭ1.4 nM), 7) differences in the atom at the 5-postion of the benzocycloheptene ring were considered to have little effect on CCR5 antagonistic activity. However, in contrast, changes in the atom at the 5-postion of the tertiary amine derivatives, was found to affect activity.
Therefore, while retaining the tertiary amine moiety of 2, other changes in the benzocycloheptene ring were investigated ( Table 2 ). Replacement of the benzocycloheptene ring with the 1-benzothiepine ring 11a slightly increased activity, and the 1-benzothiepine-1,1-dioxide 11b and the 1-benzothiepine-1-oxide 11c showed 3 to 5-fold more potent activity (IC 50 values: 0.20 and 0.30 mM, respectively). In addition, the 1-benzazepine ring was examined and N-methyl-1-benzazepine 18 was found to exhibit more than 10-fold greater potency (IC 50 valueϭ0.13 mM), than benzocycloheptene 2. The pharmacokinetic parameters were determined for compounds 2, 11b, and 18 in rats (1 mg/kg, i.v.; 10 mg/kg, p.o.). 8) The AUCs (0-24 h) of compounds 2, 11b and 18 were 1.03, 1.55, and 1.56 mg · h/ml, respectively (10 mg/kg, p.o.), and the corresponding bioavailabilities were 48%, 52%, and 67%. These results indicate that compounds 11b and 18 possess good oral bioavailability (Ͼ50%) in rats, similar to that of compound 2.
The quaternary ammonium compound 1 is a highly potent CCR5 antagonist. Since the tertiary amine 2 showed ca. 700-fold less potency, the quaternary ammonium moiety was considered to be essential for good activity. However, the results reported herein indicate potency for the tertiary amine series can be increased by changes in the benzocycloheptene ring. In particular, 1-benzothiepine-1,1-dioxide 11b and the N-methyl-1-benzazepine 18 were found to have increased activity, and exhibited good preliminary pharmacokinetic properties. Further modifications of 1-benzothiepine-1,1-dioxides and 1-benzazepines are under investigation to find orally active CCR5 antagonists with improved profiles.
Experimental
Melting points were obtained with a Yanagimoto micro melting point apparatus and are uncorrected. Proton nuclear magnetic resonance (NMR) spectra were recorded on a Varian Gemini 200 spectrometer (200 MHz), with tetramethylsilane as the internal standard. TLC analyses were carried out on Merck Kieselgel 60 F 254 plates. Elemental analyses were carried out by Takeda Analytical Laboratories, Ltd., and are within Ϯ0.4% of the theoretical values unless otherwise noted. Chromatographic purification was carried out on silica gel columns (Kieselgel 60, 0.063-0.200 mm, Merck). Yields were not optimized.
4-[(4-Bromophenyl)thio]butanoic Acid (4)
A mixture of 3 (125 g, 0.66 mol), ethyl 4-bromobutyrate (135 g, 0.69 mol) and K 2 CO 3 (109 g, 0.79 mol) in DMF (1.2 l) was stirred at room temperature for 2 h. Water was added, and the aqueous mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. To a solution of the residue in EtOH (1.5 l) was added 1 N NaOH (800 ml), and the mixture was stirred for 3 h. The mixture was concentrated in vacuo, and the residue was extracted with water. After being washed with EtOAc, the aqueous layer was acidified using HCl and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo to give 172 g (96%) of 4 as colorless crystals: mp 118-119°C. 1 
7-(4-Methylphenyl)-3,4-dihydro-1-benzothiepin-5(2H)-one (6)
A mixture of 5 (17.8 g, 69.2 mmol), 4-methylphenylboronic acid (10.0 g, 73.6 mmol), EtOH (100 ml) and 2 M K 2 CO 3 (100 ml) in toluene (300 ml) was stirred at room temperature under argon atmosphere for 30 min. Tetrakis(triphenylphosphine)palladium (3.2 g, 2.77 mmol) was added, and the mixture was refluxed for 3.5 h under argon atmosphere. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ9 : 1) to give 17.9 g (99%) of 6 as colorelss crystals: mp 108-109°C. 1 
Methyl 7-(4-Methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylate (7)
To a solution of methyl 7-(4-methylphenyl)-5-oxo-2,3,4,5-tetrahydro-1-benzothiepine-4-carboxylate (13.9 g, 42.6 mmol) in CH 2 Cl 2 (250 ml), was added a mixture of NaBH 4 (2.4 g, 63.4 mmol) in MeOH below Ϫ10°C, and the mixture was stirred at Ϫ10°C for 1 h. The reaction mixture was washed with water, dried over MgSO 4 , and evaporated in vacuo. To a solution of the residue and triethylamine (18.0 ml, 0.13 mol) in CH 2 Cl 2 (250 ml), was added dropwise methanesulfonyl chloride (7.50 ml, 45.2 mmol) under ice cooling. After overnight stirring at room temperature, 1,8-diazabicyclo[5.4.0]undec-7-ene (28.0 ml, 0.187 mol) was added dropwise with ice cooling. The reaction mixture was stirred for 1 h at room temperature, washed with water, dried over MgSO 4 , and evaporated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ4 : 1) to give 6.7 g (51%) of 7 as colorless crystals: mp 108-109°C. 1 
Methyl 7-(4-Methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylate 1,1-dioxide (8)
To a solution of 7 (1.5 g, 4.8 mmol) in CH 2 Cl 2 (25 ml), mCPBA (70%, 2.4 g, 9.7 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 1 h. After aqueous Na 2 S 2 O 3 was added, the mixture was concentrated in vacuo, and the residue was extracted with EtOAc. The organic layer was washed with aqueous NaHCO 3 7-(4-Methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylic Acid (9a) A mixture of 7 (2.5 g, 8.1 mmol) and 1 N NaOH (100 ml) in MeOH (200 ml) and diethylether (100 ml) was stirred overnight at room temperature. The mixture was concentrated, acidified using 1 N HCl and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 
7-(4-Methylphenyl)-N-(4-{[methyl(tetrahydro-2H-pyran-4-yl)amino]-methyl}phenyl)-2,3-dihydro-1-benzothiepine-4-carboxamide (11a)
To a mixture of 9a (0.3 g, 1.0 mmol) in CH 2 Cl 2 (10 ml), was added oxalyl chloride (0.27 ml, 2.8 mmol) and DMF (cat. amount) under ice cooling, the mixture was stirred for 2 h at room temperature. The solvent was evaporated in vacuo. A solution of the residue in THF (15 ml) was added dropwise to a solution of 10 (0.25 g, 1.1 mmol) and triethylamine (0.42 ml, 3.0 mol) in THF (15 ml) under ice cooling, and the reaction mixture was stirred overnight at room temperature under nitrogen atmosphere. The solvent was evaporated in vacuo, and then water was addded. The aqueous mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo to give 0.45 g (90%) of 11a as colorless crystals. Recrystallized from EtOAc and hexane: mp 234-235°C. 1 
7-(4-Methylphenyl)-N-(4-{[methyl(tetrahydro-2H-pyran-4-yl)amino]-methyl}phenyl)-2,3-dihydro-1-benzothiepine-4-carboxamide 1-oxide (11c)
To a solution of 11a (0.2 g, 0.4 mmol) in CH 2 Cl 2 (50 ml), mCPBA (70%, 0.1 g, 0.4 mmol) was added below Ϫ10°C, and the mixture was stirred at that temperature for 1 h. After aqueous Na 2 S 2 O 3 was added, the mixture was concentrated in vacuo, and the residue was extracted with EtOAc. The organic layer was washed with aqueous NaHCO 3 , water and brine, dried over MgSO 4 tert-Butyl 7-Bromo-1-methyl-2,3-dihydro-1H-1-benzazepine-4-carboxylate (16a) A mixture of 15 (4.54 g, 12.7 mmol) and potassium tert-butoxide (1.43 g, 12.7 mmol) in tert-BuOH (250 ml) was stirred at reflux for 1 h. The mixture was poured into water, 1 N HCl was added, and the aqueous mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. The residue was purified by column chromatography (hexane : 
